Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Opus Genetics, Inc.: Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month data on the first three adult OPGx-LCA5 patients to be pr ...
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month ...
Why Regeneron's Price May Soon Break Out
Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...